CCM
TNGX icon

Consonance Capital Management’s Tango Therapeutics TNGX Stock Holding History

Consonance Capital Management’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-180,000
Closed -$2.05M – 27
2021
Q2 		$2.05M Hold
180,000
– – 0.25% 27
2021
Q1 		$2M Hold
180,000
– – 0.21% 34
2020
Q4 		$2.06M Hold
180,000
– – 0.19% 33
2020
Q3 		$1.86M Buy
+180,000
New +$1.84M 0.23% 26

Other funds holding TNGX

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Consonance Capital Management's TNGX Position: Q3 2021 in Review

Consonance Capital Management sold out of Tango Therapeutics (TNGX) in Q3 2021, closing a stake of 180,000 shares — an estimated $2.05M sold.

Consonance Capital Management first reported a position in TNGX in Q3 2020 and held it in 4 quarters. The position peaked at $2.06M in Q4 2020. 46 funds tracked by Wall St. Rank hold TNGX as of Q3 2021.

  • Consonance Capital Management reported no remaining Tango Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Consonance Capital Management sold 180,000 Tango Therapeutics shares in Q3 2021, an estimated $2.05M.
  • Consonance Capital Management first reported a position in Tango Therapeutics in Q3 2020 and held it in 4 quarters.
  • Consonance Capital Management's Tango Therapeutics position peaked at $2.06M in Q4 2020.
  • 46 funds tracked by Wall St. Rank held Tango Therapeutics as of Q3 2021.

Based on Consonance Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.